{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T09:06:59Z","timestamp":1779959219642,"version":"3.53.1"},"reference-count":76,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Stroke is one of the leading causes of disability and mortality worldwide, and approximately 87% of cases are acute ischemic stroke (AIS). For patients with AIS, rapid administration of reperfusion therapy within the therapeutic time window remains the most effective treatment strategy. Over the past decade, numerous high-quality clinical trials have driven rapid advances in treatment strategies. Meanwhile, increasing attention has been directed toward cytoprotective therapies aimed at mitigating ischemic and reperfusion-related brain injury, which may act synergistically with reperfusion strategies. Although many related clinical trials have failed to demonstrate clear clinical benefit, they have provided valuable insights for the development of future cytoprotective agents. This review focuses on recent advances and remaining challenges in reperfusion therapy and cytoprotection for AIS.<\/jats:p>","DOI":"10.3390\/jcdd13060229","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:00:36Z","timestamp":1779955236000},"page":"229","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Reperfusion Therapy and Cytoprotection for Acute Ischemic Stroke"],"prefix":"10.3390","volume":"13","author":[{"given":"Zihan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing 100069, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.116.025250","article-title":"Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480,687 Adults","volume":"135","author":"Wang","year":"2017","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s12975-022-01120-6","article-title":"Implications of Post-recanalization Perfusion Deficit After Acute Ischemic Stroke: A Scoping Review of Clinical and Preclinical Imaging Studies","volume":"15","author":"Franx","year":"2024","journal-title":"Transl. Stroke Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1212\/WNL.0000000000012796","article-title":"Thrombus Composition, Imaging, and Outcome Prediction in Acute Ischemic Stroke","volume":"97","author":"Joundi","year":"2021","journal-title":"Neurology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCRESAHA.121.319948","article-title":"Advances in Acute Ischemic Stroke Therapy","volume":"130","author":"Xiong","year":"2022","journal-title":"Circ. Res."},{"key":"ref_5","first-page":"10945","article-title":"2026 Guideline for the Early Management of Patients with Acute Ischemic Stroke: A Guideline from the American Heart Association\/American Stroke Association","volume":"267","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(22)01795-0","article-title":"Protecting patients during a shortage of thrombolytic agents","volume":"400","author":"Middeldorp","year":"2022","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.2165\/00003088-200241150-00001","article-title":"Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction","volume":"41","author":"Tanswell","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1073\/pnas.91.9.3670","article-title":"A faster-acting and more potent form of tissue plasminogen activator","volume":"91","author":"Keyt","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1474-4422(17)30253-3","article-title":"Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): A phase 3, randomised, open-label, blinded endpoint trial","volume":"16","author":"Logallo","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1474-4422(22)00124-7","article-title":"Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): A phase 3, randomised, open-label, blinded endpoint, non-inferiority trial","volume":"21","author":"Kvistad","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/STROKEAHA.114.008504","article-title":"Tenecteplase\u2013Tissue-Type Plasminogen Activator Evaluation for Minor Ischemic Stroke with Proven Occlusion","volume":"46","author":"Coutts","year":"2015","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(22)01054-6","article-title":"Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): A pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial","volume":"400","author":"Menon","year":"2022","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(22)02600-9","article-title":"Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): A phase 3, multicentre, open-label, randomised controlled, non-inferiority trial","volume":"401","author":"Wang","year":"2023","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1474-4422(24)00377-6","article-title":"Tenecteplase versus alteplase for acute stroke within 4\u00b75 h of onset (ATTEST-2): A randomised, parallel group, open-label trial","volume":"23","author":"Muir","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1474-4422(24)00206-0","article-title":"Tenecteplase versus alteplase for thrombolysis in patients selected by use of perfusion imaging within 4\u00b75 h of onset of ischaemic stroke (TASTE): A multicentre, randomised, controlled, phase 3 non-inferiority trial","volume":"23","author":"Parsons","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1001\/jama.2024.14721","article-title":"Tenecteplase vs. Alteplase for Patients with Acute Ischemic Stroke: The ORIGINAL Randomized Clinical Trial","volume":"332","author":"Meng","year":"2024","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/svn-2023-002396","article-title":"Tenecteplase versus alteplase for acute ischaemic stroke: A meta-analysis of phase III randomised trials","volume":"9","author":"Xiong","year":"2024","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2165\/00003495-199652040-00012","article-title":"Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction","volume":"52","author":"Noble","year":"1996","journal-title":"Drugs"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1161\/01.CIR.94.5.891","article-title":"Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators","volume":"94","author":"Bode","year":"1996","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1056\/NEJMoa2400314","article-title":"Reteplase versus Alteplase for Acute Ischemic Stroke","volume":"390","author":"Li","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s12975-022-01012-9","article-title":"Efficacy and Safety of Recombinant Human Prourokinase in Acute Ischemic Stroke: A Phase IIa Randomized Clinical Trial","volume":"13","author":"Song","year":"2022","journal-title":"Transl. Stroke Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(24)00436-8","article-title":"Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4.5 h after stroke onset (PROST-2): A phase 3, open-label, non-inferiority, randomised controlled trial","volume":"24","author":"Li","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa0804656","article-title":"Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke","volume":"359","author":"Hacke","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJMoa1813046","article-title":"Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke","volume":"380","author":"Ma","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1056\/NEJMoa2310392","article-title":"Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection","volume":"390","author":"Albers","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1161\/STROKEAHA.125.052511","article-title":"Efficacy of Tenecteplase in Large Vessel Occlusion Stroke Within 24 Hours of Symptom Onset: The ETERNAL-LVO Randomized Controlled Trial","volume":"56","author":"Yogendrakumar","year":"2025","journal-title":"Stroke"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa2402980","article-title":"Tenecteplase for Ischemic Stroke at 4.5 to 24 Hours without Thrombectomy","volume":"391","author":"Xiong","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMoa2413344","article-title":"Alteplase for Posterior Circulation Ischemic Stroke at 4.5 to 24 Hours","volume":"392","author":"Yan","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2025.12063","article-title":"Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial","volume":"334","author":"Zhou","year":"2025","journal-title":"JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/jama.2026.0210","article-title":"Tenecteplase for Acute Non\u2013Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke: The OPTION Randomized Clinical Trial","volume":"335","author":"Ma","year":"2026","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S0140-6736(25)02633-9","article-title":"Tenecteplase versus standard medical treatment for basilar artery occlusion within 24 h (TRACE-5): A multicentre, prospective, randomised, open-label, blinded-endpoint, superiority, phase 3 trial","volume":"407","author":"Xiong","year":"2026","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411587","article-title":"A randomized trial of intraarterial treatment for acute ischemic stroke","volume":"372","author":"Berkhemer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1056\/NEJMoa1503780","article-title":"Thrombectomy within 8 hours after symptom onset in ischemic stroke","volume":"372","author":"Jovin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1056\/NEJMoa1414905","article-title":"Randomized assessment of rapid endovascular treatment of ischemic stroke","volume":"372","author":"Goyal","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1056\/NEJMoa1415061","article-title":"Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke","volume":"372","author":"Saver","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa1414792","article-title":"Endovascular therapy for ischemic stroke with perfusion-imaging selection","volume":"372","author":"Campbell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(21)01341-6","article-title":"Thrombectomy for anterior circulation stroke beyond 6 h from time last known well (AURORA): A systematic review and individual patient data meta-analysis","volume":"399","author":"Jovin","year":"2022","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1056\/NEJMoa1713973","article-title":"Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging","volume":"378","author":"Albers","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1056\/NEJMoa2206317","article-title":"Trial of Endovascular Treatment of Acute Basilar-Artery Occlusion","volume":"387","author":"Tao","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJMoa2207576","article-title":"Trial of Thrombectomy 6 to 24 Hours after Stroke Due to Basilar-Artery Occlusion","volume":"387","author":"Jovin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2022.4714","article-title":"Association of Endovascular Thrombectomy vs. Medical Management with Functional and Safety Outcomes in Patients Treated Beyond 24 Hours of Last Known Well: The SELECT Late Study","volume":"80","author":"Sarraj","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa2118191","article-title":"Endovascular Therapy for Acute Stroke with a Large Ischemic Region","volume":"386","author":"Yoshimura","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJMoa2213379","article-title":"Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct","volume":"388","author":"Huo","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1474-4422(24)00278-3","article-title":"Endovascular thrombectomy for acute ischaemic stroke with established large infarct (TENSION): 12-month outcomes of a multicentre, open-label, randomised trial","volume":"23","author":"Thomalla","year":"2024","journal-title":"Lancet Neurol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1056\/NEJMoa2314063","article-title":"Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size","volume":"390","author":"Costalat","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_47","unstructured":"The Writing Committee for the TESLA Investigators, White, R., Gembreska, K., Chaubal, V., AlMajali, M., Ashouri, Y., Olvany, J.M., Ibrahim, L.A., Previti, M., and Huffaker, S. (2024). Thrombectomy for Stroke with Large Infarct on Noncontrast CT: The TESLA Randomized Clinical Trial. JAMA, 332, 1355\u20131366."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1136\/jnis-2023-021366","article-title":"Endovascular thrombectomy for large ischemic strokes: Meta-analysis of six multicenter randomized controlled trials","volume":"17","author":"Chen","year":"2025","journal-title":"J. NeuroInterv. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJMoa2214403","article-title":"Trial of Endovascular Thrombectomy for Large Ischemic Strokes","volume":"388","author":"Sarraj","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(23)01142-X","article-title":"Value of intravenous thrombolysis in endovascular treatment for large-vessel anterior circulation stroke: Individual participant data meta-analysis of six randomised trials","volume":"402","author":"Majoie","year":"2023","journal-title":"Lancet Lond. Engl."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1056\/NEJMoa2503867","article-title":"Intravenous Tenecteplase before Thrombectomy in Stroke","volume":"393","author":"Qiu","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/jama.2022.1645","article-title":"Effect of Intra-arterial Alteplase vs. Placebo Following Successful Thrombectomy on Functional Outcomes in Patients with Large Vessel Occlusion Acute Ischemic Stroke: The CHOICE Randomized Clinical Trial","volume":"327","author":"Blasco","year":"2022","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jama.2024.23480","article-title":"Intra-Arterial Urokinase After Endovascular Reperfusion for Acute Ischemic Stroke: The POST-UK Randomized Clinical Trial","volume":"333","author":"Liu","year":"2025","journal-title":"JAMA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1001\/jama.2024.23466","article-title":"Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial","volume":"333","author":"Huang","year":"2025","journal-title":"JAMA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jama.2025.10800","article-title":"Intra-arterial Tenecteplase for Acute Stroke After Successful Endovascular Therapy: The ANGEL-TNK Randomized Clinical Trial","volume":"334","author":"Miao","year":"2025","journal-title":"JAMA"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Writing Committee for the PEARL Investigators, Jin, A., Sun, B., Dai, C., Chen, H., Qiao, H., You, J., Chen, K., Wang, S., and Deng, W. (2025). Intra-Arterial Alteplase After Successful Endovascular Reperfusion in Acute Stroke: The PEARL Randomized Clinical Trial. JAMA, 334, 1728\u20131739.","DOI":"10.1001\/jama.2025.16876"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaneurol.2025.2036","article-title":"Intra-Arterial Tenecteplase After Successful Reperfusion in Large Vessel Occlusion Stroke: A Randomized Clinical Trial","volume":"82","author":"Hou","year":"2025","journal-title":"JAMA Neurol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e080489","DOI":"10.1136\/bmj-2024-080489","article-title":"Intra-arterial tenecteplase after successful endovascular recanalisation in patients with acute posterior circulation arterial occlusion (ATTENTION-IA): Multicentre randomised controlled trial","volume":"388","author":"Hu","year":"2025","journal-title":"BMJ"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/ana.70021","article-title":"Adjunctive Thrombolytics After Successful Endovascular Reperfusion: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"98","author":"Doheim","year":"2025","journal-title":"Ann. Neurol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa2411668","article-title":"Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion","volume":"392","author":"Goyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMoa2408954","article-title":"Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels","volume":"392","author":"Psychogios","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1161\/STROKEAHA.108.541128","article-title":"Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations","volume":"40","author":"Fisher","year":"2009","journal-title":"Stroke J. Cereb. Circ."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.1072873","article-title":"Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions","volume":"298","author":"Aarts","year":"2002","journal-title":"Science"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): A multicentre, double-blind, randomised controlled trial","volume":"395","author":"Hill","year":"2020","journal-title":"Lancet"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/S0140-6736(25)00194-1","article-title":"Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): A multicentre, double-blind, randomised controlled trial","volume":"405","author":"Hill","year":"2025","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(25)00193-X","article-title":"Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): A phase 2, multicentre, randomised, double-blind, placebo-controlled study","volume":"405","author":"Christenson","year":"2025","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1474-4422(24)00515-5","article-title":"Safety and efficacy of nerinetide in patients with acute ischaemic stroke enrolled in the early window: A post-hoc meta-analysis of individual patient data from three randomised trials","volume":"24","author":"Tymianski","year":"2025","journal-title":"Lancet Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ejphar.2014.06.035","article-title":"The synergetic effect of edaravone and borneol in the rat model of ischemic stroke","volume":"740","author":"Wu","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1161\/STROKEAHA.120.031197","article-title":"Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1001\/jamaneurol.2023.5716","article-title":"Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial","volume":"81","author":"Fu","year":"2024","journal-title":"JAMA Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/svn-2018-000221","article-title":"Safety and efficacy of Edaravone Dexborneol versus edaravone for patients with acute ischaemic stroke: A phase II, multicentre, randomised, double-blind, multiple-dose, active-controlled clinical trial","volume":"4","author":"Xu","year":"2019","journal-title":"Stroke Vasc. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e086850","DOI":"10.1136\/bmj-2025-086850","article-title":"Edaravone dexborneol versus placebo on functional outcomes in patients with acute ischaemic stroke undergoing endovascular thrombectomy (TASTE-2): Randomised controlled trial","volume":"392","author":"Wang","year":"2026","journal-title":"BMJ"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.18632\/aging.202338","article-title":"Dl-3-n-butylphthalide inhibits neuroinflammation by stimulating foxp3 and Ki-67 in an ischemic stroke model","volume":"13","author":"Liu","year":"2021","journal-title":"Aging"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamaneurol.2023.1871","article-title":"Efficacy and Safety of Butylphthalide in Patients with Acute Ischemic Stroke: A Randomized Clinical Trial","volume":"80","author":"Wang","year":"2023","journal-title":"JAMA Neurol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(25)01862-8","article-title":"Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): A multicentre, double-blind, randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1161\/STROKEAHA.125.052148","article-title":"Optimizing Reperfusion Trials: A Consensus Research Roadmap From the STAIR XIII Conference","volume":"57","author":"Campbell","year":"2026","journal-title":"Stroke"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/6\/229\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T08:42:47Z","timestamp":1779957767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/6\/229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":76,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcdd13060229"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13060229","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}